917910-75-9

Usage

Uses

Used in Pharmaceutical Industry:
5-((4-Methoxybenzyl)oxy)picolinonitrile is utilized as a key intermediate in the synthesis of various pharmaceutical compounds. Its unique structure and properties make it a valuable component in the development of new drugs, particularly those targeting complex biological systems.
Used in Medicinal Chemistry Research:
In the field of medicinal chemistry, 5-((4-Methoxybenzyl)oxy)picolinonitrile serves as a versatile building block for the creation of novel drug candidates. Its presence in a molecule can influence the compound's pharmacokinetics, pharmacodynamics, and overall therapeutic potential, making it an essential tool for researchers in drug discovery and design.
Used in Drug Development:
5-((4-Methoxybenzyl)oxy)picolinonitrile is employed in the research and development phase of new drugs, where its properties can be harnessed to improve the efficacy, safety, and delivery of pharmaceutical agents. Its role in the synthesis of drug candidates is crucial for advancing innovative treatments and therapies in the healthcare sector.

Upstream product

• 327056-62-2 5-fluoropicolinonitrile 
• 105-13-5 4-Methoxybenzyl alcohol 
• 97483-77-7 2-Cyano-5-bromopyridine 

Downstream Products

• 917910-76-0 4-(4-methoxybenzyloxy)-2-hydroxyamidinylpyridine 
• 1260863-04-4 tert-butyl 7-oxo-3,4,6,8,9,9a-hexahydro-1H-pyrido[1,2-a]pyrazine-2-carboxylate 
• 917911-43-4 C₂₁H₂₃N₃O₅ 
• 954149-59-8 C₁₉H₁₉N₃O₅ 
• 917910-77-1 C₁₉H₁₉N₃O₅ 
• 917911-36-5 C₁₈H₁₈N₄O₄ 
• 1022144-87-1 C₂₃H₂₆N₄O₇ 
• 1022144-83-7 C₂₇H₃₄N₄O₇ 
• 1309591-62-5 C₁₈H₂₁N₅O₅ 
• 1309591-61-4 C₁₈H₂₁N₅O₅ 

Relevant academic research and scientific papers

Amine compound inhibiting SSAO/VAP-1 and application thereof in medicine

The invention relates to an amine compound for inhibiting semicarbazide-sensitive amine oxidase (SSAO) and/or vascular adhesion protein 1 (VAP-1) and medicinal application thereof, and further relatesto a pharmaceutical composition containing the compound

OCTAHYDROPYRIDO[1,2-ALPHA]PYRAZINES AS MAGL INHIBITORS

The invention provides new heterocyclic compounds having the general formula (le), wherein R1, R1a and R7 are as described herein, compositions including the compounds, processes of manufacturing the compounds and methods

NITROGEN-CONTAINING AROMATIC HETEROCYCLYL COMPOUND

The present invention provides a compound having excellent regulating action on blood lipid level. The present invention provides a compound represented by the following general formula (I) or a pharmacologically acceptable salt thereof, etc., wherein A represents a 5-membered nitrogen-containing aromatic heterocyclyl group; R1 represents COOH or the like; each R2 represents an alkyl or the like; each R3 represents an optionally substituted phenyl, an optionally substituted phenylalkyl, or the like; m represents 0, 1, 2, or 3; n represents 0 or 1; each of R4, R5, R6, and R7 represents H, an alkyl, or the like; and B represents an optionally substituted naphthyl, an optionally substituted aromatic heterocyclyl, or a group represented by the following formula (II) wherein each of B1 and B2 represents an optionally substituted phenyl or an optionally substituted aromatic heterocyclyl.

The discovery of high affinity agonists of GPR109a with reduced serum shift and improved ADME properties

Amino-anthranilic acid derivatives have been identified as a new class of low serum shifted, high affinity full agonists of the human orphan G-protein-coupled receptor GPR109a with improved ADME properties.

Discovery of a biaryl cyclohexene carboxylic acid (MK-6892): A potent and selective high affinity niacin receptor full agonist with reduced flushing profiles in animals as a preclinical candidate

Biaryl cyclohexene carboxylic acids were discovered as full and potent niacin receptor (GPR 109A) agonists. Compound 1e (MK-6892) displayed excellent receptor activity, good PK across species, remarkably clean off-target profiles, good ancillary pharmacology, and superior therapeutic window over niacin regarding the FFA reduction versus vasodilation in rats and dogs.

Niacin Receptor Agonists, Compositions Containing Such Compounds and Methods of Treatment

The present invention encompasses compounds of Formula I: as well as pharmaceutically acceptable salts and hydrates thereof, that are useful for treating atherosclerosis, dyslipidemias and the like. Pharmaceutical compositions and methods of use are also included.

NIACIN RECEPTOR AGONISTS, COMPOSITIONS CONTAINING SUCH COMPOUNDS AND METHODS OF TREATMENT

The present invention encompasses compounds of Formula (I) as well as pharmaceutically acceptable salts and hydrates thereof, that are useful for treating atherosclerosis, dyslipidemias and the like. Pharmaceutical compositions and methods of use are also

NIACIN RECEPTOR AGONISTS, COMPOSITIONS CONTAINING SUCH COMPOUNDS AND METHODS OF TREATMENT

The present invention encompasses compounds of Formula (I): as well as pharmaceutically acceptable salts and hydrates thereof, that are useful for treating atherosclerosis, dyslipidemias and the like. Pharmaceutical compositions and methods of use are also included.

NIACIN RECEPTOR AGONISTS, COMPOSITIONS CONTAINING SUCH COMPOUNDS AND METHODS OF TREATMENT

The present invention encompasses compounds of Formula (I) as well as pharmaceutically acceptable salts and hydrates thereof, that are useful for treating atherosclerosis, dysliptdemias and the like. Pharmaceutical compositions and methods of use are also

Discovery of biaryl anthranilides as full agonists for the high affinity niacin receptor

Biaryl anthranilides are reported as potent and selective full agonists for the high affinity niacin receptor GPR109A. The SAR presented outlines approaches to reduce serum shift and both CYPCYP2C8 and CYP2C9 liabilities, while improving PK and maintainin